Sign in
Taking people in CzechiaPhase 2

Testing Low-Dose Albumin to Protect Blood Vessels After Ischemic Stroke

Tests low-dose albumin, a blood protein, in adults with ischemic stroke.

Key facts

Who runs it
Fakultni Nemocnice Hradec Kralove
Where
Hradec Králové, CzechiaSee the site
Registry title
Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx with Low-Dose Albumin Administration (MOZEG)
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
9 Feb 2026
Expected to end
3 Mar 2027
Type of study
Interventional
Record updated
26 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a stroke caused by a blocked blood vessel in the front part of the brain, who need a procedure to remove the clot. It tests low-dose albumin to protect the blood vessel lining.

Age
18 years or older
Sex
All sexes can join
Disease stage
Ischemic stroke in the anterior circulation (the front part of the brain), with or without clot-dissolving treatment, and a planned procedure to open the vessel by mechanical recanalization at a stroke center
Earlier treatment
No other trial of an investigational medicine within 30 days before screening

Main reasons for not taking part

  • Known allergy to albumin products or their ingredients
  • Signs or risk of too much fluid in the body, such as acute heart failure or lung edema
  • Other conditions listed as contraindications for Alburex, such as life-threatening bleeding with anemia or kidney failure
  • Sodium in the blood above 150 mmol/L
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Provision of consent to participate in the clinical study by the patient or an independent physician, depending on the patient’s medical condition
  • Diagnosis of ischemic stroke (iCMP) in the anterior circulation, with or without thrombolysis
  • Indication for a vasographic intervention – mechanical recanalization at a stroke center
  • For women of childbearing potential: Willingness to use highly effective methods of contraception throughout the clinical trial and until Day 21 (inclusive) after administration of the investigational medicinal product. Given the medical condition of the enrolled patients, complete sexual abstinence appears to be the most appropriate option

Who cannot take part

  • Participation in another clinical trial involving an investigational medicinal product within 30 days prior to screening
  • Signs of hypervolemia and hyperhydration or risk of their development (e.g., symptoms of acute heart failure or decompensated chronic heart failure, such as anasarca or pulmonary edema)
  • Signs of other conditions listed as contraindications in the SmPC for Alburex (e.g., bleeding from esophageal varices or other life-threatening hemorrhage associated with anemia, renal failure /renal or post-renal/)
  • Known hypersensitivity to albumin preparations or their excipients
  • Hypernatremia > 150 mmol/L
  • Pregnancy or breastfeeding

Where in Czechia

  • Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaTaking people

About the trial

What the trial wants to find out

Evaluation of the efficacy of albumin as a protection for the glycocalyx and endothelial functions.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx with Low-Dose Albumin Administration (MOZEG)
Plain-language title
Testing Low-Dose Albumin to Protect Blood Vessels After Ischemic StrokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 March 2025